Publications

• ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer

  Sahm SW, Neumann UP, Zahn MO, Schwittay M, Maintz C, Goehler T, Rubanov O, Hering-Schubert C, Janssen J, Stenzel K, Reinke J, Overkamp F.

  PMID: 41742069 Show Details link to full text
  Study

  ERBITAG

  Year

  2026

  Keywords

  • cetuximab
  • colorectal cancer

• EVOLUTION-HF DEallEF: A non-interventional study of patients with heart failure initiated on dapagliflozin: study design

  Matthias Paul, Ralph Bosch, Behrus Subin, Angelika Guth, Marlena Mueller, Mareike Seelinger, Stephanie Riemann, Birgit Assmus

  PMID: PMC12287773 Show Details link to full text
  Study

  EVOLUTION-HF

  Year

  2025

  Keywords

  • dapagliflozin
  • heart failure

• InspeCKD – Analyse zur Prävalenz, Diagnose und Therapie der chronischen Nierenerkrankung

  Christoph Wanner MD, Elke Schaeffner MD, Thomas Frese MD, Ulrich Opfermann MD, Frank Radowsky MD, Philipp Stahl MD, Fabian Burckhardt MD, Felix Scherg MD, Christoph Weber MD & Frederik Mader MD

  PMID: Show Details link to full text
  Study

  InspeCKD

  Year

  2025

  Keywords

  • CKD

• Effectiveness of switching to doravirine-based antiretroviral therapy: A real-world study in Germany

  C. Wyen, M. Sabranski, C. Jonsson-Oldenbüttel, J. Bogner, H. Knechten, S. Esser, N. Qurishi, S. Schellberg, I. Kolobova, J.-P. Pelz, Y. O. Whiteside, B. K. Tadese, J. K. Rockstroh

  PMID: 40613664 Show Details link to full text
  Study

  NIS VICDOR

  Year

  2025

  Keywords

• Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot study

  Santorelli ML, Schmalz O, Hoiczyk M, Heigener D, Schulte C, Knott M, Hoffknecht P, Vainio J, Burke T, Norquist JM, Riehl S, Hildner A, Barthuber L, Bohnet S

  PMID: 40677515 Show Details link to full text
  Study

  Lung AID

  Year

  2025

  Keywords

  • pembrolizumab

• Whitepaper zu Identifikation, Information und Eignungsprüfung von potenziellen Teilnehmern an der Lungenkrebsfrüherkennung in Deutschland

  T. G. Blum, J. Vogel-Claussen, H. Hoffmann, M. Reck, V. Harth, A. Faron, I. Dänschel, S. Andreas, A. Rupp, R. Kaaks, G. Schmid-Bindert

  PMID: 41086827 Show Details link to full text
  Study

  Year

  2025

  Keywords

  • lung cancer

• Effectiveness of NELSON versus PLCOm2012 Lung Cancer Screening Eligibility Criteria – the German Prospective Multicenter HANSE Study

  J. Vogel-Claussen, B.A. Bollmann, K. May, S. Stiebeler, S. Dettmer, A. Faron, A. Kuhlmann, G. Schmid-Bindert, R. Kaaks, J. Barkhausen, S. Bohnet, M. Reck for the HANSE investigators

  PMID: 41232542 Show Details link to full text
  Study

  HANSE

  Year

  2025

  Keywords

  • lung cancer

• DETECT IPN: Real-World Experience with Automated Detection of Incidental Pulmonary Nodules in an All-Comer Population

  Johannes Dunsche, Hans-Ulrich Kauczor, Oyunbileg V. Stackelberg, Isabelle Ayx, Rimma Kondrashova, Jens Vogel-Claussen, Joana Lamché, Gerald Schmid-Bindert

  PMID: 10.4236/ojrad.2025.151002 Show Details link to full text
  Study

  DETECT IPN

  Year

  2025

  Keywords

  • lung cancer

• Incidental Pulmonary Nodules: What Should We Do in 2026?

  Gerald Schmid-Bindert, Jens Vogel-Claussen, Benjamin-Alexander Bollmann, Joana Lamché, Martin E. Eichhorn, Felix Herth

  PMID: 41363795 Show Details link to full text
  Study

  Year

  2025

  Keywords

  • lung cancer

• real-world use of teriflunomide in Germany and changes in treatment patterns over time

  B.-A. Kallmann, G. Zu Eulenburg, J.S. Kullmann, M. Mäurer

  PMID: 38808094 Show Details link to full text
  Study

  TAURUS-MS II

  Year

  2024

  Keywords

  • multiple sclerosis